Abstract
Periprocedural myocardial injury is a prognostically important complication of percutaneous coronary intervention (PCI). However, it still remains unclear whether and how intensive atorvastatin therapy attenuates the unfavorable inflammatory responses of monocytes associated with PCI. The aim of the study was to investigate the impact of intensive atorvastatin therapy on inflammatory responses of monocytes in Chinese patients with unstable angina who received PCI in order to explore the potential anti-inflammatory mechanism. Ninety-six patients with unstable angina were randomly assigned to atorvastatin 80 mg (intensive) or atorvastatin 20 mg (conventional) treatment at a 1:1 ratio. Creatine kinase MB (CK-MB), cTnI, hs-CRP, and IL-6 were assessed, and circulating CD14+ monocytes were simultaneously obtained using CD14 MicroBeads 2 h before and 24 h after PCI. Plasma levels of CK-MB, cTnI, hs-CRP, and IL-6 were higher in the conventional dose group versus those in the intensive dose group following PCI. Furthermore, intensive atorvastatin treatment markedly reduced the expressions and responses of Toll-like receptor 2 (TLR2), TLR4, and CCR2 of CD14+ monocytes versus the conventional dose group and significantly increased the activated peroxisome-proliferator-activated receptor (PPAR) γ in the CD14+ monocytes post-PCI. Notably, the changes in responses of TLR2, TLR4, and CCR2 of CD14+ monocytes between the two groups were all reversed by PPARγ antagonist and augmented by PPARγ agonist. In conclusion, a single high (80 mg) loading dose of atorvastatin reduced the inflammatory response in Chinese patients with unstable angina following PCI. The anti-inflammatory role of intensive atorvastatin was possibly due to attenuation of inflammatory response in monocytes via PPARγ activation.
Similar content being viewed by others
References
Nusca, A., R. Melfi, G. Patti, and G.D. Sciascio. 2010. Statin loading before percutaneous coronary intervention: proposed mechanisms and applications. Future Cardiology 6: 579–89.
Briel, M., N. Vale, G.G. Schwartz, J.A. de Lemos, F. Colivicchi, F.R. den Hartog, et al. 2012. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. International Journal of Cardiology 158: 93–100.
Pasceri, V., G. Patti, A. Nusca, C. Pristipino, G. Richichi, G. Di Sciascio, et al. 2004. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation 110: 674–8.
Patti, G., M. Chello, V. Pasceri, D. Colonna, A. Nusca, M. Miglionico, et al. 2006. Protection from procedural myocardial injury by atorvastatin is associated with lower levels of adhesion molecules after percutaneous coronary intervention: results from the ARMYDA-CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudy. Journal of the American College of Cardiology 48: 1560–6.
Patti, G., V. Pasceri, G. Colonna, M. Miglionico, D. Fischetti, G. Sardella, et al. 2007. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. Journal of the American College of Cardiology 49: 1272–8.
Norris, D.M., and J.R. Anderson. 2012. Statin loading before percutaneous coronary intervention to reduce periprocedural myocardial infarction. Cardiology in Review 20: 319–24.
Briguori, C., G. Visconti, A. Focaccio, B. Golia, A. Chieffo, A. Castelli, et al. 2009. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. Journal of the American College of Cardiology 54: 2157–63.
Toutouzas, K., A. Colombo, and C. Stefanadis. 2004. Inflammation and restenosis after percutaneous coronary interventions. European Heart Journal 25: 1679–87.
Liuzzo, G., A. Buffon, L.M. Biasucci, J.R. Gallimore, G. Caligiuri, A. Vitelli, et al. 1998. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation 98: 2370–6.
Liuzzo, G., M. Santamaria, L.M. Biasucci, M. Narducci, V. Colafrancesco, A. Porto, et al. 2007. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation. Journal of the American College of Cardiology 49: 185–94.
Norata, G.D., K. Garlaschelli, M. Ongari, S. Raselli, L. Grigore, F. Benvenuto, et al. 2005. Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. Journal of Internal Medicine 258: 21–7.
Candore, G., A. Aquino, C.R. Balistreri, M. Bulati, D. Di Carlo, M.P. Grimaldi, et al. 2006. Inflammation, longevity, and cardiovascular diseases: role of polymorphisms of TLR4. Annals of the New York Academy of Sciences 1067: 282–7.
Akira, S., and K. Takeda. 2004. Toll-like receptor signalling. Nature Reviews Immunology 4: 499–511.
Sakai, N., T. Wada, K. Furuichi, K. Shimizu, S. Kokubo, A. Hara, et al. 2006. MCP-1/CCR2-dependent loop for fibrogenesis in human peripheral CD14-positive monocytes. Journal of Leukocyte Biology 79: 555–63.
Schober, A., A. Zernecke, E.A. Liehn, P. von Hundelshausen, S. Knarren, W.A. Kuziel, et al. 2004. Crucial role of the CCL2/CCR2 axis in neointimal hyperplasia after arterial injury in hyperlipidemic mice involves early monocyte recruitment and CCL2 presentation on platelets. Circulation Research 95: 1125–33.
Das, S.K., and R. Chakrabarti. 2006. Role of PPAR in cardiovascular diseases. Recent Patents on Cardiovascular Drug Discovery 1: 193–209.
Francis, G.A., J.S. Annicotte, and J. Auwerx. 2003. PPAR agonists in the treatment of atherosclerosis. Current Opinion in Pharmacology 3: 186–91.
Grip, O., S. Janciauskiene, and S. Lindgren. 2002. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflammation Research: Official Journal of the European Histamine Research Society [et al] 51: 58–62.
Yano, M., T. Matsumura, T. Senokuchi, N. Ishii, Y. Murata, K. Taketa, et al. 2007. Statins activate peroxisome proliferator-activated receptor gamma through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages. Circulation Research 100: 1442–51.
Sanchez-Margalet, V., J.M. Cubero, C. Martin-Romero, J. Cubero, J.M. Cruz-Fernandez, and R. Goberna. 2002. Inflammatory response to coronary stent implantation in patients with unstable angina. Clinical Chemistry and Laboratory Medicine: CCLM / FESCC 40: 769–74.
Novack, V., M. Pencina, D.J. Cohen, N.S. Kleiman, C.H. Yen, J.F. Saucedo, et al. 2012. Troponin criteria for myocardial infarction after percutaneous coronary intervention. Archives of Internal Medicine 172: 502–8.
Arefieva, T.I., T.L. Krasnikova, A.V. Potekhina, N.U. Ruleva, P.I. Nikitin, T.I. Ksenevich, et al. 2011. Synthetic peptide fragment (65-76) of monocyte chemotactic protein-1 (MCP-1) inhibits MCP-1 binding to heparin and possesses anti-inflammatory activity in stable angina patients after coronary stenting. Inflammation Research: Official Journal of the European Histamine Research Society [et al] 60: 955–64.
Dewald, O., P. Zymek, K. Winkelmann, A. Koerting, G. Ren, T. Abou-Khamis, et al. 2005. CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts. Circulation Research 96: 881–9.
Frangogiannis, N.G., O. Dewald, Y. Xia, G. Ren, S. Haudek, T. Leucker, et al. 2007. Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy. Circulation 115: 584–92.
Ziegler-Heitbrock, L., P. Ancuta, S. Crowe, M. Dalod, V. Grau, D.N. Hart, et al. 2010. Nomenclature of monocytes and dendritic cells in blood. Blood 116: e74–80.
Acknowledgments
This work was supported by Tangshan Science & Technology program (13130254a).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, J., Liu, C., Zhang, L. et al. Intensive Atorvastatin Therapy Attenuates the Inflammatory Responses in Monocytes of Patients with Unstable Angina Undergoing Percutaneous Coronary Intervention via Peroxisome Proliferator-Activated Receptor γ Activation. Inflammation 38, 1415–1423 (2015). https://doi.org/10.1007/s10753-015-0116-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-015-0116-2